April 18, 2017
The Society for Immunotherapy of Cancer (SITC) has joined the world’s leading organizations representing clinicians, laboratory researchers and physician-scientists committed to improving patient care in support of the March for Science and its nonpartisan call for the appreciation of scientific evidence, education and investment.
Issued by the American Society of Hematology, and signed on by 25 of the foremost medical organizations in the world, the press release acknowledges research supported by the National Institutes of Health has yielded significant scientific advances and reiterates the critical need to preserve appropriate funding in cancer research. As noted in the statement, “Today, diseases with previously grim prognoses are treatable. We have powerful therapies that engage the patient’s own immune system to conquer cancers and non-malignant diseases.”
As the leading voice for the field of immunotherapy – one of the most promising areas of cancer research – SITC supports the March for Science and encourages its members and others committed to advancing health care to celebrate the critical role science plays in our lives.
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.